Literature DB >> 17313987

Efficient siRNA delivery using water soluble lipopolymer for anti-angiogenic gene therapy.

Won Jong Kim1, Chien-Wen Chang, Minhyung Lee, Sung Wan Kim.   

Abstract

We examined the potential application of a non-viral gene carrier, water soluble lipopolymer (WSLP) for delivering siRNA targeting vascular endothelial growth factor (VEGF) in vitro and in vivo. WSLP was complexed with siRNA designed to inhibit human VEGF expression or scrambled siRNA as a control. WSLP readily formed nano-sized complexes ( approximately 100 nm) with siRNA and protected siRNAs from enzymatic degradation in serum conditioned media. WSLP/siRNA complexes were transfected in PC-3 cells derived from human prostate adenocarcinomas and, then the siRNA delivery efficiency of the complexes was evaluated by VEGF production inhibition assay. VEGF production was efficiently inhibited by the WSLP/siRNA complexes, while complexes of WSLP with scrambled siRNA did not show this inhibitory effect. WSLP/siRNA complexes reduced the VEGF production by 40% when compared to unmodified branched polyethylenimine (bPEI, MW=1800). Moreover, WSLP/siRNA complexes reduced tumor volume by 55% at 21 days, and by 65% at 28 days when compared to controls. These results indicate that WSLP has potential as a siRNA delivering agent and can be applied for anti-angiogenic tumor therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17313987     DOI: 10.1016/j.jconrel.2006.12.026

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  23 in total

Review 1.  Nonviral delivery of synthetic siRNAs in vivo.

Authors:  Saghir Akhtar; Ibrahim F Benter
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

Review 2.  Efficient siRNA delivery with non-viral polymeric vehicles.

Authors:  Won Jong Kim; Sung Wan Kim
Journal:  Pharm Res       Date:  2008-11-18       Impact factor: 4.200

3.  Improved intratumoral delivery of PEG-coated siRNA-lipoplexes by combination with metronomic S-1 dosing in a murine solid tumor model.

Authors:  Tatsuaki Tagami; Amr S Abu Lila; Mariko Matsunaga; Naoto Moriyoshi; Hiroyuki Nakamura; Kazuya Nakamura; Takuya Suzuki; Yusuke Doi; Tatsuhiro Ishida; Hiroshi Kiwada
Journal:  Drug Deliv Transl Res       Date:  2012-04       Impact factor: 4.617

4.  Balancing polymer hydrophobicity for ligand presentation and siRNA delivery in dual function CXCR4 inhibiting polyplexes.

Authors:  Y Wang; J Li; Y Chen; D Oupický
Journal:  Biomater Sci       Date:  2015-07       Impact factor: 6.843

Review 5.  Polymers in small-interfering RNA delivery.

Authors:  Kaushik Singha; Ran Namgung; Won Jong Kim
Journal:  Nucleic Acid Ther       Date:  2011-06       Impact factor: 5.486

6.  PEI-g-PEG-RGD/small interference RNA polyplex-mediated silencing of vascular endothelial growth factor receptor and its potential as an anti-angiogenic tumor therapeutic strategy.

Authors:  Jihoon Kim; Sung Wan Kim; Won Jong Kim
Journal:  Oligonucleotides       Date:  2011-03-04

7.  Nanomedicines for Endothelial Disorders.

Authors:  Bomy Lee Chung; Michael J Toth; Nazila Kamaly; Yoshitaka J Sei; Jacob Becraft; Willem J M Mulder; Zahi A Fayad; Omid C Farokhzad; YongTae Kim; Robert Langer
Journal:  Nano Today       Date:  2015-12-01       Impact factor: 20.722

Review 8.  Engineering RNA for targeted siRNA delivery and medical application.

Authors:  Peixuan Guo; Oana Coban; Nicholas M Snead; Joe Trebley; Steve Hoeprich; Songchuan Guo; Yi Shu
Journal:  Adv Drug Deliv Rev       Date:  2010-03-15       Impact factor: 15.470

9.  Tumor-targeted delivery of siRNA by self-assembled nanoparticles.

Authors:  Shyh-Dar Li; Yun-Ching Chen; Michael J Hackett; Leaf Huang
Journal:  Mol Ther       Date:  2007-10-09       Impact factor: 11.454

10.  Phospholipid-polyethylenimine conjugate-based micelle-like nanoparticles for siRNA delivery.

Authors:  Gemma Navarro; Rupa R Sawant; Sean Essex; Conchita Tros de Ilarduya; Vladimir P Torchilin
Journal:  Drug Deliv Transl Res       Date:  2011-02-01       Impact factor: 4.617

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.